Search

Sartorius Stedim Biotech.

Chiusa

SettoreFinanza

214.1 -0.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

210.7

Massimo

217.4

Metriche Chiave

By Trading Economics

Entrata

-28M

64M

Vendite

-39M

706M

P/E

Media del settore

79.114

26.043

EPS

0.94

Margine di Profitto

9.097

Dipendenti

10,134

EBITDA

16M

218M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+11.63% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

691M

21B

Apertura precedente

214.33

Chiusura precedente

214.1

Notizie sul Sentiment di mercato

By Acuity

29%

71%

81 / 493 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 gen 2026, 19:05 UTC

I principali Market Mover

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 gen 2026, 23:41 UTC

Discorsi di Mercato

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 gen 2026, 23:41 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 gen 2026, 23:33 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 gen 2026, 23:13 UTC

Acquisizioni, Fusioni, Takeovers

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 gen 2026, 23:10 UTC

Acquisizioni, Fusioni, Takeovers

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 gen 2026, 23:03 UTC

Discorsi di Mercato

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 gen 2026, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

13 gen 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 gen 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 gen 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 gen 2026, 21:15 UTC

Acquisizioni, Fusioni, Takeovers

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 gen 2026, 21:08 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 gen 2026, 20:39 UTC

Discorsi di Mercato

Silver Settles at Another New High -- Market Talk

13 gen 2026, 20:21 UTC

Discorsi di Mercato

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 gen 2026, 20:17 UTC

Discorsi di Mercato

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 gen 2026, 19:08 UTC

Acquisizioni, Fusioni, Takeovers

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 gen 2026, 19:03 UTC

Utili

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 gen 2026, 18:50 UTC

Utili

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 gen 2026, 17:54 UTC

Discorsi di Mercato

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 gen 2026, 17:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

13 gen 2026, 17:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 gen 2026, 17:49 UTC

Discorsi di Mercato

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 gen 2026, 17:38 UTC

Discorsi di Mercato

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 gen 2026, 17:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

13 gen 2026, 17:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

13 gen 2026, 17:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

13 gen 2026, 17:19 UTC

Discorsi di Mercato

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 gen 2026, 17:15 UTC

Discorsi di Mercato

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

11.63% in crescita

Previsioni per 12 mesi

Media 240 EUR  11.63%

Alto 260 EUR

Basso 210 EUR

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

4

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

81 / 493 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat